Why Is TE Connectivity (TEL) Down 2.6% Since Last Earnings Report?

TE Connectivity (TEL) reported robust third-quarter fiscal 2025 results, with adjusted EPS of $2.27 (up 18.8% YoY) and net sales of $4.53 billion (up 14% reported, 9% organic), both surpassing consensus estimates, largely driven by strong performance in its Industrial segment. Despite these positive financials and an optimistic Q4 guidance projecting continued growth, TEL shares have declined 2.6% since the earnings release, underperforming the S&P 500. Nevertheless, analyst estimates have trended upward, resulting in a Zacks Rank #2 (Buy) and indicating expectations for future above-average returns.

Analysis

TE Connectivity (TEL) has demonstrated a significant disconnect between its strong operational performance and recent stock trajectory. The company reported robust third-quarter fiscal 2025 results, with adjusted EPS of $2.27 and revenue of $4.53 billion, beating consensus estimates by 9.1% and 5.2% respectively. This top-line growth of 14% year-over-year (9% organic) was primarily driven by its Industrial Solutions segment, which surged 30% on a reported basis, masking modest growth in Transportation Solutions (2.8%) and a notable 13.4% decline in the Medical sub-segment. Operationally, the company expanded its adjusted operating margin by 60 basis points to 19.9% and generated substantial free cash flow of $962 million. Despite this fundamental strength, a positive Q4 guidance forecasting 12% sales growth, and a 7.14% upward revision in consensus analyst estimates, the stock has declined 2.6% over the past month, underperforming the S&P 500 and earning a poor 'F' grade for momentum.

Key Decisions for Investors

• The recent share price decline of 2.6% despite a significant earnings beat and strong forward guidance may present a buying opportunity for investors focused on fundamentals over short-term price momentum.
• It is crucial to assess the sustainability of the Industrial segment's high growth, which is currently compensating for softness in the Transportation segment's sensor sales and a decline in the Medical business.
• Given the positive Q4 guidance and upward revisions in analyst estimates, which resulted in a Zacks #2 (Buy) rating, the stock's current underperformance could be transient, suggesting a potential for an above-average return in the coming months.